sōna曲霉半乳甘露聚糖侧向层析法在癌症患者中的性能评估
该研究评估了sōna曲霉半乳甘露聚糖侧向层析法(GM LFA)在癌症患者中的分析性能和临床性能,并与Bio-Rad半乳甘露聚糖酶免疫法(GM EIA)进行比较。GM LFA与GM EIA的总体阳性符合率(PPA)为100%(95%CI 72.2-100%),阴性符合率(NPA)为97.5%(95%CI 95.5-98.4%)。GM LFA对确诊和临床诊断侵袭性曲霉病的敏感性分别为100%(95%CI 51.0-100%)和87.5%(95%CI 55.9-99.4%),特异性分别为95.5%(95%CI 92.3-97.2%)和96.2%(95%CI 93.4-97.7%)。GM LFA在检测半乳甘露聚糖抗原方面优于GM EIA,且操作简便、结果快速,易于在各类实验室开展。
要点
- GM LFA与GM EIA的总体阳性符合率为100%,阴性符合率为97.5%。
- GM LFA对确诊侵袭性曲霉病的敏感性为100%,对临床诊断的敏感性为87.5%。
- GM LFA操作简便、结果快速,适合广泛实验室应用。
核心结论
- 在癌症患者人群中,sōna曲霉半乳甘露聚糖侧向层析法(GM LFA)检测半乳甘露聚糖抗原的性能优于Bio-Rad半乳甘露聚糖酶免疫法(GM EIA)。
研究设计与样本
- 计算GM LFA与GM EIA相比的阳性符合率(PPA)和阴性符合率(NPA),并通过查阅病历对不一致结果进行分析。
主要发现
- GM LFA与GM EIA的总体PPA为100%(95%CI 72.2-100%),NPA为97.5%(95%CI 95.5-98.4%)。
- GM LFA对确诊侵袭性曲霉病的敏感性为100%(95%CI 51.0-100%),特异性为95.5%(95%CI 92.3-97.2%)。
- GM LFA对临床诊断侵袭性曲霉病的敏感性为87.5%(95%CI 55.9-99.4%),特异性为96.2%(95%CI 93.4-97.7%)。
- GM EIA对确诊侵袭性曲霉病的敏感性为25%(95%CI 1.28-69.9%),特异性为98.2%(95%CI 96.2-99.1%);对临床诊断的敏感性为62.5%(95%CI 30.6-86.3%),特异性为99.2%(95%CI 97.7-99.8%)。
关键数值与推荐
- GM LFA与GM EIA的总体PPA为100%(95%CI 72.2-100%),NPA为97.5%(95%CI 95.5-98.4%)。
- GM LFA对确诊侵袭性曲霉病的敏感性为100%(95%CI 51.0-100%),特异性为95.5%(95%CI 92.3-97.2%)。
- GM LFA对临床诊断侵袭性曲霉病的敏感性为87.5%(95%CI 55.9-99.4%),特异性为96.2%(95%CI 93.4-97.7%)。
临床怎么用
- GM LFA操作简便、结果快速,易于在各类实验室环境中实施。
- 在癌症患者中,GM LFA可作为检测半乳甘露聚糖抗原的可行方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The diagnosis of invasive aspergillosis can be challenging in cancer patients. Herein, the analytical and clinical performance of the sōna Aspergillus galactomannan lateral flow assay (GM LFA) was evaluated and its performance compared to that of the Bio-Rad galactomannan enzyme immunoassay (GM EIA). Serum and bronchoalveolar lavage (BAL) fluid samples received for GM EIA testing between March and August 2019 were included. Positive and negative percent agreement (PPA and NPA) were calculated for the GM LFA compared to the GM EIA. Discrepant analysis was performed by review of the patient's medical records assessing for any evidence of a fungal infection. Five hundred thirty-three samples (85 BAL samples and 448 serum samples) from 379 patients were included in the study. The overall PPA and NPA were 100% (95% confidence interval [CI], 72.2 to 100%) and 97.5% (95% CI, 95.5 to 98.4%), respectively. Fourteen of 24 samples were positive by LFA only. The sensitivity of the GM LFA for proven and probable invasive aspergillosis (IA) was 100% (95% CI, 51.0 to 100%) and 87.5% (95% CI, 55.9 to 99.4%), with a specificity of 95.5% (95% CI, 92.3 to 97.2%) and 96.2% (95% CI, 93.4 to 97.7%), respectively. The sensitivity of the GM EIA for proven and probable IA was 25% (95% CI, 1.28 to 69.9%) and 62.5% (95% CI, 30.6 to 86.3%), with a specificity of 98.2% (95% CI, 96.2 to 99.1%) and 99.2% (95% CI, 97.7 to 99.8%), respectively. The Aspergillus GM LFA outperformed the Aspergillus GM EIA for the detection of the galactomannan antigen in our patient population. The simplicity and rapid time to results makes the Aspergillus GM LFA easy to implement in a wide range of laboratory settings.
引用
- Jani K, McMillen T, Morjaria S, et al. Performance of the sōna Aspergillus Galactomannan Lateral Flow Assay in a Cancer Patient Population. J Clin Microbiol. 2021. PMID: 34232067. doi:10.1128/JCM.00598-21
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。